Literature DB >> 2650954

Saturable pharmacokinetics in the renal excretion of drugs.

C A van Ginneken1, F G Russel.   

Abstract

The renal excretion of drugs is the result of different mechanisms: glomerular filtration, passive back diffusion, tubular secretion and tubular reabsorption. Of these mechanisms the last 2 are saturable, as they involve carrier transport. This also implies that both tubular secretion and tubular reabsorption are susceptible to competition between similar substrates for a common carrier site. Furthermore, transport via these mechanisms is energy-dependent, so-called active transport, able to concentrate a drug. Tubular secretion takes place in the proximal tubule of the nephron. Many organic compounds are actively secreted, but there are separate carrier systems for anions and cations. Anions appear to be transported actively over the basolateral membrane and by a less efficient non-active carrier-mediated process (facilitated diffusion) over the brush border membrane. As a result of these mechanisms, anions tend to accumulate in proximal tubular cells. For cations, however, the active transport step operates over the brush border membrane, whereas the uptake of the cation in the cell occurs via facilitated diffusion over the basolateral membrane. Active reabsorption is most prominent for many nutrients and endogenous substrates (amino acids, glucose, vitamins), but various exogenous compounds also have a certain affinity for the reabsorptive carrier systems. Uricosuric drugs, for instance, interfere with carrier-mediated reabsorption of urate. The occurrence of saturable excretion routes causes dose-dependent, non-linear pharmacokinetics. In clinical pharmacokinetics, tubular secretion can adequately be described with the use of a Michaelis-Menten equation. This implies that a compound undergoing tubular secretion exhibits a concentration-dependent renal clearance. At low plasma concentrations the clearance will be maximal, and for several drugs may be as high as the effective renal plasma flow. Increasing concentrations cause decreasing renal clearance, until eventually the secretion mechanism becomes fully saturated. Then the excretion of the drug in urine will depend primarily on its net rate of filtration. It is important to realise that the non-linear kinetics will be evident from the plasma kinetics only when the saturable pathway contributes to at least some 20% of the total body clearance. Interactions with other substrates, however, are likely to occur even when only a very small amount of drug is transported by the carrier system. Non-linear kinetics inevitably lead to disproportionate accumulation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650954     DOI: 10.2165/00003088-198916010-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  158 in total

Review 1.  The disposition and metabolism of captopril.

Authors:  O H Drummer; B Jarrott
Journal:  Med Res Rev       Date:  1986 Jan-Mar       Impact factor: 12.944

2.  Saturation of the tubular excretion of beta-lactam antibiotics.

Authors:  J W Bins; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Transformation and excretion of drugs in biological systems. VII. Effect of biotransformation on renal excretion of sulfonamides.

Authors:  T Arita; R Hori; M Takada; S Akuzu; A Misawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1972-03       Impact factor: 1.645

4.  The effect of dietary protein-calorie restriction on the renal elimination of cimetidine.

Authors:  L M Gersema; G D Park; T M Kitt; R Spector
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

5.  Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.

Authors:  M Muirhead; F Bochner; A Somogyi
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

6.  Development of mechanisms for drug excretion.

Authors:  J B Hook; W R Hewitt
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

7.  Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.

Authors:  A Rakhit; G M Kochak; V Tipnis; M E Hurley
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

8.  Is 125I iothalamate an ideal marker for glomerular filtration?

Authors:  B Odlind; R Hällgren; M Sohtell; B Lindström
Journal:  Kidney Int       Date:  1985-01       Impact factor: 10.612

9.  The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study.

Authors:  N Baber; L Halliday; R Sibeon; T Littler; M L Orme
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

10.  Pharmacokinetics: metabolism and renal excretion of quinolones in man.

Authors:  T B Vree; W J Wijnands; P J Guelen; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
View more
  30 in total

1.  Urinary excretion: does it accurately reflect relative differences in bioavailability/systemic exposure when renal clearance is nonlinear?

Authors:  Gary A Thompson; Roger D Toothaker
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.

Authors:  C Padoin; M Tod; G Perret; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 4.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

5.  The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit.

Authors:  V Pichette; D Geadah; P du Souich
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

6.  Altered flecainide disposition in healthy volunteers taking quinine.

Authors:  A Munafo; G Reymond-Michel; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.

Authors:  François Gimenez; Estelle Foeillet; Olivier Bourdon; Steve Weller; Christophe Garret; Roselyne Bidault; Eric Singlas
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.

Authors:  A Jacolot; M Tod; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfadimethoxine in man.

Authors:  T B Vree; E W Beneken Kolmer; M Martea; R Bosch; Y A Hekster; M Shimoda
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

10.  Influence of the unbound concentration of cefonicid on its renal elimination in isolated perfused rat kidneys.

Authors:  C A Rodriguez; D E Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.